Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.94
ALQA's Cash-to-Debt is ranked lower than
63% of the 790 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. ALQA: 0.94 )
Ranked among companies with meaningful Cash-to-Debt only.
ALQA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: No Debt Max: No Debt
Current: 0.94
Equity-to-Asset 0.67
ALQA's Equity-to-Asset is ranked higher than
56% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALQA: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
ALQA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.82 Max: 0.99
Current: 0.67
0.57
0.99
Piotroski F-Score: 3
Altman Z-Score: -2.20
Beneish M-Score: -1.79
WACC vs ROIC
15.30%
-37.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -83.64
ALQA's Operating Margin % is ranked lower than
86% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.64 vs. ALQA: -83.64 )
Ranked among companies with meaningful Operating Margin % only.
ALQA' s Operating Margin % Range Over the Past 10 Years
Min: -1119.69  Med: -398.45 Max: -51.07
Current: -83.64
-1119.69
-51.07
Net Margin % -73.74
ALQA's Net Margin % is ranked lower than
86% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.21 vs. ALQA: -73.74 )
Ranked among companies with meaningful Net Margin % only.
ALQA' s Net Margin % Range Over the Past 10 Years
Min: -1222.3  Med: -399.1 Max: -52.73
Current: -73.74
-1222.3
-52.73
ROE % -29.35
ALQA's ROE % is ranked lower than
83% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.92 vs. ALQA: -29.35 )
Ranked among companies with meaningful ROE % only.
ALQA' s ROE % Range Over the Past 10 Years
Min: -312.57  Med: -70.75 Max: -16.22
Current: -29.35
-312.57
-16.22
ROA % -18.37
ALQA's ROA % is ranked lower than
80% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. ALQA: -18.37 )
Ranked among companies with meaningful ROA % only.
ALQA' s ROA % Range Over the Past 10 Years
Min: -2368.45  Med: -89.26 Max: -15.45
Current: -18.37
-2368.45
-15.45
ROC (Joel Greenblatt) % -553.82
ALQA's ROC (Joel Greenblatt) % is ranked lower than
88% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.01 vs. ALQA: -553.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALQA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53854.55  Med: -1397.71 Max: -55.94
Current: -553.82
-53854.55
-55.94
3-Year Revenue Growth Rate 41.90
ALQA's 3-Year Revenue Growth Rate is ranked higher than
93% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. ALQA: 41.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALQA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 41.9
Current: 41.9
0
41.9
3-Year EBITDA Growth Rate 8.60
ALQA's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.50 vs. ALQA: 8.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALQA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -67.6  Med: 26.45 Max: 108.9
Current: 8.6
-67.6
108.9
3-Year EPS without NRI Growth Rate 7.50
ALQA's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.30 vs. ALQA: 7.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALQA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 24.05 Max: 115
Current: 7.5
0
115
GuruFocus has detected 3 Warning Signs with Alliqua BioMedical Inc $ALQA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALQA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALQA Guru Trades in Q1 2016

Jim Simons 137,800 sh (+589.00%)
» More
Q2 2016

ALQA Guru Trades in Q2 2016

Jim Simons 271,500 sh (+97.02%)
» More
Q3 2016

ALQA Guru Trades in Q3 2016

Jim Simons 333,000 sh (+22.65%)
» More
Q4 2016

ALQA Guru Trades in Q4 2016

Jim Simons 410,400 sh (+23.24%)
» More
» Details

Insider Trades

Latest Guru Trades with ALQA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2899
Compare:AMEX:CPHI, OTCPK:INNV, NAS:TNXP, NAS:BSPM, OTCPK:INBP, OTCPK:SUWN, OTCPK:ECTE, OTCPK:CHEXF, OTCPK:ENZB, NAS:IMNP, AMEX:AXN, NAS:NVGN, NAS:PRPH, OTCPK:PXSLY, AMEX:NNVC, OTCPK:BIOYF, NAS:ALIM, NAS:OASM, NAS:ZGNX, NAS:RMTI » details
Traded in other countries:HL1A.Germany,
Alliqua BioMedical Inc is a biomedical company providing wound care solutions. It is also engaged in contract manufacturing.

Alliqua BioMedical Inc a Florida corporation formed on October 21, 1997. It is a biomedical company through its subsidiary providing advanced wound care solutions. The Company's core business includes; advanced wound care and contract manufacturing. The Company develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its subsidiary manufactures and markets its hydrogel products. Its products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable it to produce gels that can satisfy rigid tolerance specifications with respect to a range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. In July 2012, it began to market two proprietary products, SilverSeal, a hydrogel wound dressing with silver coated fibers, and Hydress, an over-the-counter hydrogel wound dressing. It supplies these gels mainly to the wound care segment of the healthcare industry. The Company's SilverSeal and Hydress dressings are each currently available in two sizes and are used to provide and maintain a moist wound environment. SilverSeal dressings also provide an antimicrobial barrier. On November 14, 2013 Company entered into a license, marketing and development agreement with Anthrogenesis Corporation, Celgene Cellular Therapeutics ("CCT"), an affiliate of Celgene Corporation, pursuant to which CCT granted an exclusive, royalty-bearing license in its intellectual property related to certain placental based products, including the wound care products Extracellular Matrix ("ECM"), a suite of advanced wound management products made from extracellular matrix derived from the human placenta and Biovance, a collagen-based decellularized and dehydrated topical wound covering produced from human amniotic membrane for the management of non-infected partial- and full-thickness wounds; and also into a supply agreement with CCT, pursuant to which CCT will supply Company with the entire requirement of Biovance for distribution and sale in the United States. The Company's medical devices are subject to the U.S. Food and Drug Administration's general controls, which include compliance with the applicable portions of the U.S. Food and Drug Administration's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U

Ratios

vs
industry
vs
history
PB Ratio 0.28
ALQA's PB Ratio is ranked higher than
98% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. ALQA: 0.28 )
Ranked among companies with meaningful PB Ratio only.
ALQA' s PB Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.48 Max: 23.18
Current: 0.28
0.28
23.18
PS Ratio 0.58
ALQA's PS Ratio is ranked higher than
91% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. ALQA: 0.58 )
Ranked among companies with meaningful PS Ratio only.
ALQA' s PS Ratio Range Over the Past 10 Years
Min: 0.58  Med: 10.3 Max: 38.71
Current: 0.58
0.58
38.71
EV-to-EBIT -0.88
ALQA's EV-to-EBIT is ranked lower than
99.99% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. ALQA: -0.88 )
Ranked among companies with meaningful EV-to-EBIT only.
ALQA' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.5  Med: -2.6 Max: -0.3
Current: -0.88
-15.5
-0.3
EV-to-EBITDA -1.19
ALQA's EV-to-EBITDA is ranked lower than
99.99% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. ALQA: -1.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALQA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -99.1  Med: -2.9 Max: -0.4
Current: -1.19
-99.1
-0.4
Current Ratio 0.91
ALQA's Current Ratio is ranked lower than
88% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ALQA: 0.91 )
Ranked among companies with meaningful Current Ratio only.
ALQA' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.29 Max: 96.93
Current: 0.91
0.04
96.93
Quick Ratio 0.74
ALQA's Quick Ratio is ranked lower than
85% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. ALQA: 0.74 )
Ranked among companies with meaningful Quick Ratio only.
ALQA' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.96 Max: 96.93
Current: 0.74
0.04
96.93
Days Inventory 151.53
ALQA's Days Inventory is ranked lower than
67% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. ALQA: 151.53 )
Ranked among companies with meaningful Days Inventory only.
ALQA' s Days Inventory Range Over the Past 10 Years
Min: 11.87  Med: 54.54 Max: 111.22
Current: 151.53
11.87
111.22
Days Sales Outstanding 47.49
ALQA's Days Sales Outstanding is ranked higher than
75% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. ALQA: 47.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALQA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.55  Med: 34.04 Max: 73.9
Current: 47.49
13.55
73.9
Days Payable 125.48
ALQA's Days Payable is ranked higher than
78% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. ALQA: 125.48 )
Ranked among companies with meaningful Days Payable only.
ALQA' s Days Payable Range Over the Past 10 Years
Min: 24.61  Med: 113.85 Max: 196.17
Current: 125.48
24.61
196.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -67.20
ALQA's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. ALQA: -67.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALQA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.2  Med: -14.5 Max: 30.3
Current: -67.2
-67.2
30.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.06
ALQA's Price-to-Median-PS-Value is ranked higher than
99% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ALQA: 0.06 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALQA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.96 Max: 3.19
Current: 0.06
0.1
3.19
Earnings Yield (Greenblatt) % -113.60
ALQA's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ALQA: -113.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALQA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -421.86  Med: 0 Max: 0
Current: -113.6
-421.86
0

More Statistics

Revenue (TTM) (Mil) $20.79
EPS (TTM) $ -0.53
Beta1.15
Short Percentage of Float1.28%
52-Week Range $0.45 - 1.48
Shares Outstanding (Mil)29.67

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 19 38 54 65
EPS ($) -0.56 -0.40 -0.23 -0.08
EPS without NRI ($) -0.56 -0.40 -0.23 -0.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALQA

Headlines

Articles On GuruFocus.com
CFO of Alliqua BioMedical Inc Buys 2,500 Shares Aug 12 2015 
Market Overlooks Alliqua’s First MAC Coverage Apr 21 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jan 30 2017
ETFs with exposure to Alliqua BioMedical, Inc. : January 3, 2017 Jan 03 2017
Hedge Funds Aren’t Crazy About A. M. Castle & Co (CASL) Anymore Dec 20 2016
ETFs with exposure to Alliqua BioMedical, Inc. : December 8, 2016 Dec 08 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Dec 02 2016
ALLIQUA BIOMEDICAL, INC. Financials Nov 15 2016
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and... Nov 10 2016
ETF’s with exposure to Alliqua BioMedical, Inc. : November 8, 2016 Nov 08 2016
Alliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 Nov 07 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 04 2016
Alliqua BioMedical, Inc. Reports Third Quarter and Nine-Months Fiscal Year 2016 Financial Results Nov 04 2016
ETF’s with exposure to Alliqua BioMedical, Inc. : October 20, 2016 Oct 20 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Oct 18 2016
Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement Coverage for MIST Therapy® Oct 10 2016
ETF’s with exposure to Alliqua BioMedical, Inc. : October 7, 2016 Oct 07 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation... Oct 06 2016
Alliqua BioMedical, Inc. to Acquire Soluble Systems, LLC Oct 05 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 05 2016
Alliqua BioMedical, Inc. Announces Preliminary Third Quarter of Fiscal Year 2016 Revenue; Earnings... Oct 05 2016
Alliqua BioMedical, Inc. Expands Regenerative Medicine Portfolio with the Commercial Introduction of... Sep 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)